[ad_1]
AstraZeneca, a pharmaceutical company, said Sunday that no scientific evidence suggests that the vaccine developed by the company against the new type of coronavirus would increase the risk of blood clots.
As a prelude to a statement issued by the British-Swedish Pharmaceutical Group in London on Sunday night, several countries – Norway, Bulgaria, Denmark, Iceland and Italy and Ireland on Sunday – have decided to suspend the use of a vaccine jointly developed by AstraZeneca. . and Oxford University following a reported blood clot case in some patients vaccinated with this vaccine.
However, AstraZeneca highlighted in a statement Sunday that a careful safety study of the more than 17 million doses of vaccines administered so far in the European Union and the United Kingdom has not provided any evidence that the vaccine is used anywhere. age group, in any country, in any gender, or increase the risk of pulmonary embolism, deep vein thrombosis (DVT) or abnormal platelet counts in any vaccine shipment. The company said
based on data received up to March 8, there were 15 cases of deep vein thrombosis and 22 cases of pulmonary embolism in the European Union and the UK among those vaccinated with AstraZeneca / Oxford.
This is far less than the number of cases that can occur in a population of this size for natural reasons and is similar to the number of cases reported after the use of other licensed vaccines, AstraZeneca reported Sunday night.
Ann Taylor, AstraZenca’s chief medical officer, also said in a statement to the announcement that 17 million patients vaccinated with the company’s vaccine have reported fewer cases of blood clots than would be the case in the general population, with hundreds of patients. Similar. would be expected.
According to AstraZeneca, there were no confirmed quality issues with any of the vaccine shipments.
The company is closely monitoring reports of blood clots, but available data does not prove that these were caused by the vaccine, the company said in a statement Sunday night.
The UK Medicines Agency (MHRA) also said in its daily report that there was no confirmed causal link between the AstraZeneca vaccine and the cases of blood clots found.
In a statement Thursday, the MHRA emphasized that 11 million doses of AstraZeneca had so far been administered in the UK and that there were no more reports of blood clots than there would have been for natural reasons in the vaccinated population during the same period. period.
[ad_2]
